口服华法林与骨质疏松性骨折的关联性研究

Association between oral administration of warfarin and osteoporotic fracture

目的:确定口服华法林与骨质疏松性骨折发生是否有关。方法:回顾性分析2004年3月至2015年3月收治的口服华法林患者1519例临床资料,选取基线情况适合患者4704例作为对照组,分别计算口服华法林1年、2年、3年、4年、5年及以上患者发生骨质疏松性骨折的风险优势比(OR)。结果:口服华法林组整体骨质疏松性骨折及髋部骨折发生率均较对照组显著升高(P<0.05),而口服华法林5年以上的骨质疏松性骨折发生率极显著升高(P<0.01)。结论:长期使用华法林将使骨折风险度增高,这种效应在髋部骨折中表现尤为明显。

Objective： To determine the association between oral administration of warfarin and the occurrence of osteoporotic fracture. Methods： The clinical data of 1519 patients receiving oral administration of warfarin was retrospectively analyzed from March 2004 to March 2015. 4704 patients with matched baseline status were selected as control group. Odds ratios （OR） ofosteoporotic fracture risk were calculated after 1-, 2 -, 3 -, 4 -, 5-year and above 5-year oral administration of warfarin. Results： Theincidences of overall osteoporotic fracture and hip fracture in oral warfarin group were significantly highegroup of （ P 〈 0. 05 ）,and the incidence of osteoporotic fracture in patients orally given warfarin more significantly （ P 〈0. 01 ）. Conclusion： Long-term use of warfarin may increase the risk of fracture,particularly in hip fracture.